Federal Register Notice: FDA’s Cardiovascular and Renal Drugs Advisory Committee will be held 9/10, from 8:30 a.m. to 5 p.m. at the Holiday Inn, Bethesda, MD. The committee will discuss an NDA for AstraZeneca’s Exanta 24 mg 36 mg tablets for the proposed indication of preventing venous thromboembolism (VTE) in patients undergoing knee replacement surgery, preventing stroke and other thromboembolic complications associated with atrial fibrillation and the long-term secondary prevention of VTE after standard treatment of an episode of acute VTE. Contact Dornette Spell-LeSane, (301) 827-7001. To view this notice, click here.
